Travis B Lewis
Overview
Explore the profile of Travis B Lewis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cirnaru M, Creus-Muncunill J, Nelson S, Lewis T, Watson J, Ellerby L, et al.
Mov Disord
. 2021 Aug;
36(12):2780-2794.
PMID: 34403156
Background: X-linked dystonia parkinsonism is a generalized, progressive dystonia followed by parkinsonism with onset in adulthood and accompanied by striatal neurodegeneration. Causative mutations are located in a noncoding region of...
2.
Nasrallah M, Nasrallah I, Prelack M, Johnson M, Lewis T, Rubenstein M, et al.
Brain Pathol
. 2017 Jun;
27(4):557-558.
PMID: 28585383
No abstract available.
3.
Lewis T, Glasgow J, Harms A, Standaert D, Curiel D
Viruses
. 2014 Sep;
6(8):3293-310.
PMID: 25196484
Gene-based therapies for neurological diseases continue to develop briskly. As disease mechanisms are elucidated, flexible gene delivery platforms incorporating transcriptional regulatory elements, therapeutic genes and targeted delivery are required for...
4.
5.
Lewis T, Glasgow J, Glandon A, Curiel D, Standaert D
PLoS One
. 2010 Sep;
5(9).
PMID: 20862245
Background: Gene-based therapy is a new paradigm for the treatment of Parkinson disease (PD) and offers considerable promise for precise targeting and flexibility to impact multiple pathobiological processes for which...
6.
Lewis T, Standaert D
Exp Neurol
. 2007 Oct;
209(1):41-7.
PMID: 17920590
No current therapy for Parkinson disease has been shown to slow or reverse the progressive course of the disease. As a departure from traditional treatments, gene therapy approaches provide a...
7.
Boska M, Lewis T, Destache C, Benner E, Nelson J, Uberti M, et al.
J Neurosci
. 2005 Feb;
25(7):1691-700.
PMID: 15716405
Nigrostriatal degeneration, the pathological hallmark of Parkinson's disease (PD), is mirrored by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. MPTP-treated animals show the common behavioral, motor, and pathological features of human disease. We demonstrated...
8.
Benner E, Mosley R, Destache C, Lewis T, Jackson-Lewis V, Gorantla S, et al.
Proc Natl Acad Sci U S A
. 2004 Jun;
101(25):9435-40.
PMID: 15197276
Degeneration of the nigrostriatal dopaminergic pathway, the hallmark of Parkinson's disease, can be recapitulated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice. Herein, we demonstrate that adoptive transfer of copolymer-1 immune cells to MPTP...
9.
Boska M, Mosley R, Nawab M, Nelson J, Zelivyanskaya M, Poluektova L, et al.
Curr HIV Res
. 2004 Apr;
2(1):61-78.
PMID: 15053341
Persons with advanced human immunodeficiency virus type one (HIV-1) infection seek medical advice for a wide range of neurological disorders including, but not limited to, peripheral neuropathy, toxoplasmosis, cryptococcal meningitis,...